Seema A. Bhat, MD

home / authors / seema-a-bhat-md

Articles

Seema A. Bhat, MD, of The Ohio State University Comprehensive Cancer Center–James

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

Seema A. Bhat, MD
October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Read More

Seema A. Bhat, MD, of The Ohio State University Comprehensive Cancer Center–James,

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

Seema A. Bhat, MD
October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Read More

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

Seema A. Bhat, MD
October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Read More

Seema A. Bhat, MD

Dr. Bhat on Emerging Targeted Therapies in CLL

Seema A. Bhat, MD
October 14th 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Read More

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

Seema A. Bhat, MD
October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Read More

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

Seema A. Bhat, MD
October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Read More

Dr. Bhat on the Role of Targeted Therapies in CLL

Dr. Bhat on the Role of Targeted Therapies in CLL

Seema A. Bhat, MD
October 2nd 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data